Literature DB >> 7910473

Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists has no influence on the pharmacokinetics of ethanol after a moderate dose.

A Mallat1, F Roudot-Thoraval, J F Bergmann, H Trout, G Simonneau, C Dutreuil, L E Blanc, D Dhumeaux, J C Delchier.   

Abstract

Ethanol undergoes gastric first pass metabolism by alcohol dehydrogenase (ADH). We have shown that cimetidine and famotidine both cause competitive inhibition of human gastric ADH in vitro. However, in a randomized 4-way cross-over study in 12 healthy subjects a 7-day course of treatment with cimetidine (800 mg day-1), ranitidine (300 mg day-1) or famotidine (40 mg day-1), did not modify the pharmacokinetics of ethanol given as a post-prandial 0.3 g kg-1 dose. We conclude that gastric mucosal concentrations of histamine H2-receptor blockers achieved after oral dosing are probably too low to cause significant inhibition of gastric ADH in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910473      PMCID: PMC1364600          DOI: 10.1111/j.1365-2125.1994.tb04263.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  [Evaluation of a technique for determining blood ethanol levels by gas chromatography. Committee for "determination of blood ethanol levels"].

Authors:  J M Warnet; C Boudène; J L Cluet; E François; J P Goulle; Y Le Hanaff; A Leblanc; F Lenegre; M Leymarie; B Mousson
Journal:  Ann Biol Clin (Paris)       Date:  1990       Impact factor: 0.459

2.  Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels.

Authors:  J Caballeria; E Baraona; M Rodamilans; C S Lieber
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

3.  Effects of fasting and chronic alcohol consumption on the first-pass metabolism of ethanol.

Authors:  C DiPadova; T M Worner; R J Julkunen; C S Lieber
Journal:  Gastroenterology       Date:  1987-05       Impact factor: 22.682

4.  First pass metabolism of ethanol--a gastrointestinal barrier against the systemic toxicity of ethanol.

Authors:  R J Julkunen; C Di Padova; C S Lieber
Journal:  Life Sci       Date:  1985-08-12       Impact factor: 5.037

5.  High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism.

Authors:  M Frezza; C di Padova; G Pozzato; M Terpin; E Baraona; C S Lieber
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

Review 6.  Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-02       Impact factor: 9.546

7.  Characterization of three isoenzymes of rat alcohol dehydrogenase. Tissue distribution and physical and enzymatic properties.

Authors:  P Julià; J Farrés; X Parés
Journal:  Eur J Biochem       Date:  1987-01-02

8.  Sex differences in gastric alcohol dehydrogenase activity in Sprague-Dawley rats.

Authors:  E Mezey; S Sharma; L Rennie; J J Potter
Journal:  Gastroenterology       Date:  1992-12       Impact factor: 22.682

9.  Purification and characterization of a new alcohol dehydrogenase from human stomach.

Authors:  A Moreno; X Parés
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

Review 10.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

View more
  2 in total

Review 1.  Pharmacokinetic interactions between alcohol and other drugs.

Authors:  A G Fraser
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

2.  Effect of histamine-2 receptor antagonists on blood alcohol levels: a meta-analysis.

Authors:  D S Weinberg; D Burnham; J A Berlin
Journal:  J Gen Intern Med       Date:  1998-09       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.